Monday, February 11, 2013

Novo Nordisk hit hard as U.S. rebuffs insulin drug

By Mette Fraende COPENHAGEN (Reuters) – U.S. regulators refused to approve Novo Nordisk’s new long-acting insulin Tresiba until it conducts extra tests for potential heart risks, dealing a major blow to a key product for the Danish drugmaker. Shares in Novo, the world’s...
Novo Nordisk hit hard as U.S. rebuffs insulin drug